Latest Earnings Results: Q3 '26
Estimated EPS
$0.18
Reported EPS
$0.06
Surprise
-66.67%
Estimated Rev
$142.59M
Reported Rev
$143.92M
Surprise
+0.93%
• Reported GAAP EPS of $0.06 • Reported revenue of $143.92M up 45.05% YoY
Bullish Takeaway
Arcutis Biotherapeutics reported product revenue growth with greater patient demand, pursued a ZORYVE infant indication expansion, and enrolled the first atopic dermatitis patient in ARQ-234s multiple ascending dose trial.
Bearish Takeaway
Arcutis Biotherapeutics faces rising commercialization and development costs, uncertainty about future profitability and potential financing needs, while relying on third-party manufacturers, including single-source suppliers.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.20 | -- | -- | N/A |
Q3 '26 | $0.18 | $0.06 | -66.67% | MISSED |
Q2 '26 | $0.06 | $0.11 | 99.73% | BEAT |
Q1 '26 | -$0.06 | -$0.09 | -39.91% | MISSED |
Q4 '25 | $0.09 | $0.13 | 40.75% | BEAT |